Cargando…

Rce1: mechanism and inhibition

Ras converting enzyme 1 (Rce1) is an integral membrane endoprotease localized to the endoplasmic reticulum that mediates the cleavage of the carboxyl-terminal three amino acids from CaaX proteins, whose members play important roles in cell signaling processes. Examples include the Ras family of smal...

Descripción completa

Detalles Bibliográficos
Autores principales: Hampton, Shahienaz E., Dore, Timothy M., Schmidt, Walter K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874806/
https://www.ncbi.nlm.nih.gov/pubmed/29424242
http://dx.doi.org/10.1080/10409238.2018.1431606
_version_ 1783310235096580096
author Hampton, Shahienaz E.
Dore, Timothy M.
Schmidt, Walter K.
author_facet Hampton, Shahienaz E.
Dore, Timothy M.
Schmidt, Walter K.
author_sort Hampton, Shahienaz E.
collection PubMed
description Ras converting enzyme 1 (Rce1) is an integral membrane endoprotease localized to the endoplasmic reticulum that mediates the cleavage of the carboxyl-terminal three amino acids from CaaX proteins, whose members play important roles in cell signaling processes. Examples include the Ras family of small GTPases, the γ-subunit of heterotrimeric GTPases, nuclear lamins, and protein kinases and phosphatases. CaaX proteins, especially Ras, have been implicated in cancer, and understanding the post-translational modifications of CaaX proteins would provide insight into their biological function and regulation. Many proteolytic mechanisms have been proposed for Rce1, but sequence alignment, mutational studies, topology, and recent crystallographic data point to a novel mechanism involving a glutamate-activated water and an oxyanion hole. Studies using in vivo and in vitro reporters of Rce1 activity have revealed that the enzyme cleaves only prenylated substrates and the identity of the a(2) amino residue in the Ca(1)a(2)X sequence is most critical for recognition, preferring Ile, Leu, or Val. Substrate mimetics can be somewhat effective inhibitors of Rce1 in vitro. Small-molecule inhibitor discovery is currently limited by the lack of structural information on a eukaryotic enzyme, but a set of 8-hydroxyquinoline derivatives has demonstrated an ability to mislocalize all three mammalian Ras isoforms, giving optimism that potent, selective inhibitors might be developed. Much remains to be discovered regarding cleavage specificity, the impact of chemical inhibition, and the potential of Rce1 as a therapeutic target, not only for cancer, but also for other diseases.
format Online
Article
Text
id pubmed-5874806
institution National Center for Biotechnology Information
language English
publishDate 2018
record_format MEDLINE/PubMed
spelling pubmed-58748062018-04-01 Rce1: mechanism and inhibition Hampton, Shahienaz E. Dore, Timothy M. Schmidt, Walter K. Crit Rev Biochem Mol Biol Article Ras converting enzyme 1 (Rce1) is an integral membrane endoprotease localized to the endoplasmic reticulum that mediates the cleavage of the carboxyl-terminal three amino acids from CaaX proteins, whose members play important roles in cell signaling processes. Examples include the Ras family of small GTPases, the γ-subunit of heterotrimeric GTPases, nuclear lamins, and protein kinases and phosphatases. CaaX proteins, especially Ras, have been implicated in cancer, and understanding the post-translational modifications of CaaX proteins would provide insight into their biological function and regulation. Many proteolytic mechanisms have been proposed for Rce1, but sequence alignment, mutational studies, topology, and recent crystallographic data point to a novel mechanism involving a glutamate-activated water and an oxyanion hole. Studies using in vivo and in vitro reporters of Rce1 activity have revealed that the enzyme cleaves only prenylated substrates and the identity of the a(2) amino residue in the Ca(1)a(2)X sequence is most critical for recognition, preferring Ile, Leu, or Val. Substrate mimetics can be somewhat effective inhibitors of Rce1 in vitro. Small-molecule inhibitor discovery is currently limited by the lack of structural information on a eukaryotic enzyme, but a set of 8-hydroxyquinoline derivatives has demonstrated an ability to mislocalize all three mammalian Ras isoforms, giving optimism that potent, selective inhibitors might be developed. Much remains to be discovered regarding cleavage specificity, the impact of chemical inhibition, and the potential of Rce1 as a therapeutic target, not only for cancer, but also for other diseases. 2018-02-09 2018-04 /pmc/articles/PMC5874806/ /pubmed/29424242 http://dx.doi.org/10.1080/10409238.2018.1431606 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Article
Hampton, Shahienaz E.
Dore, Timothy M.
Schmidt, Walter K.
Rce1: mechanism and inhibition
title Rce1: mechanism and inhibition
title_full Rce1: mechanism and inhibition
title_fullStr Rce1: mechanism and inhibition
title_full_unstemmed Rce1: mechanism and inhibition
title_short Rce1: mechanism and inhibition
title_sort rce1: mechanism and inhibition
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874806/
https://www.ncbi.nlm.nih.gov/pubmed/29424242
http://dx.doi.org/10.1080/10409238.2018.1431606
work_keys_str_mv AT hamptonshahienaze rce1mechanismandinhibition
AT doretimothym rce1mechanismandinhibition
AT schmidtwalterk rce1mechanismandinhibition